Unversität Zürich

Novartis Ag

Onur Boyman

Chao Zou

Natalia Arenas-Ramirez

Barbara Brannetti

Andreas Katopodis

Iwan Beuvink

Simone Popp

Catherine Regnier

The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.

Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof

The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (K)&#x2264;7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (K)&#x2264;1&#xd7;10sand/or the antibody displays no measurable cross-reactivity to murine IL-2.

Immune-stimulating monoclonal antibodies against human interleukin-2

Growing community of inventors

Küsnacht, Switzerland

Onur Boyman